WhitePaper | What's Hot & What's Not in Oncology Licensing


What's Hot & What's Not in Oncology Licensing 

This whitepaper is based on a live web panel, hosted by ShareVault and the Biotechnology Industry Organization (BIO), discussing what's exciting in cancer drug development versus what is not popular in licensing, and why.

For the live event, biotech licensing, and pharmaceutical business development consultant Linda Pullan was joined by three panelists who are business development experts from a global pharmaceutical company, a leading academic cancer center, and a top business development consulting firm. The panelists discussed  theories of cancer, favorite targets and modalities, the impact of reimbursement, deal types, and more .

In addition to the complete written coverage of the panel discussion, the white paper, authored and edited by the panelists, provides fresh content: responses to questions received during the panel that were not answered due to time constraints.

If you are developing a cancer drug or working toward in- or out-licensing of a cancer drug, you will want to read these perspectives.


VIEW THE
WHITEPAPER

ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives pharmaceutical and biotechnology  organizations the confidence to simply and securely share sensitive documents with third parties during due diligence, product development, technology transfers, fundraising, partnering, collaborative research and other activities that require the highest level of document security.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.

WHITEPAPER  AUTHOR:

David-Stastny_headshot
Linda Pullan, PhD - Moderator

Pullan Consulting

Linda offers biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a Ph.D. in Biochemistry, a B.S. in Chemistry, and more than twenty years of drug industry experience. Learn More

David-Stastny_headshot
Jeff Bockman, PhD

Vice President, Defined Health

Jeff leads the Oncology and Virology Practices at Defined Health. He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Learn More

David-Stastny_headshot
Paul Juniewicz

Vice President, Oncology Business Opportunities, Sanofi

Paul is currently the North American Head of Oncology Business Opportunities (OBO) within the Strategic Portfolio and Management Group of the Oncology Division for Sanofi. Paul is responsible for scouting and evaluating external oncology opportunities and possible research collaborations. Learn More

David-Stastny_headshot
Ferran Prat, PhD

VP of Strategic Industry Ventures, MD Anderson

Ferran helps the faculty and researchers at MD Anderson develop collaborative opportunities with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners. Learn More


Sponsored by: